Archive

Volume 8, Number 2 / August issue 2022
Mohamed Abdel-Hady Mashahit, Shahira Morsy El-Shafeey, Hala Sayed El-Toukhy, Ragab Adly Ali, Hossam M. Abdel Aziz, Mahmoud Gamal Ali
Clinical applications of carbamylated hemoglobin in renal diseases
Abstract

Carbamylated hemoglobin is formed by reaction of isocyanate (urea dissociation product) with valine residues of Hb chains. Different studies demonstrated that carbamylated hemoglobin level is increased in patients with renal impairment. This study concluded that carbamylated hemoglobin level significantly correlates with serum creatinine (r=0.411, moderate positive) and urea level (r=0.408, moderate positive) (p<0.001). This correlation may be important in clinical settings makes carbamylated hemoglobin good biomarker for renal impairment, and may reflect severity and duration of renal impairment. We also found that carbamylated hemoglobin level is not affected by the diabetes state of the patient.
Keywords: Carbamylated hemoglobin, urea dissociation products, renal impairment, kidney biomarkers

Cite this article:
Mohamed Abdel-Hady Mashahit, Shahira Morsy El-Shafeey, Hala Sayed El-Toukhy, Ragab Adly Ali, Hossam M. Abdel Aziz, Mahmoud Gamal Ali. Clinical applications of carbamylated hemoglobin in renal diseases. Acta Scientiae et Intellectus, 8(2); 2022, 53-59.


REFERENCES

  1. Berg A.H., Drechsler C., Wenger J., et al., (2013). Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med.; 5:175ra29.
  2. Ibrahim S., Fayed A., and Belal D. (2016): Spectrum of renal diseases among patients admitted to the internal medicine unit through the emergency room and their outcomes: morbidity, mortality, and cost analysis. Journal of the Egyptian Society of Nephrology and Transplantation, 16:16-20.
  3. Jonathan T., Edwin C., Jeffrey L., et al., (1992): Carbamylated haemoglobin in normal, diabetic and uraemic patients. Ann Clin Biochem 1992; 29: 206-209.
  4. Kalim S., Karumanchi A., Thadhani R. et al., (2014). Protein Carbamylation in Kidney Disease: Pathogenesis and Clinical Implications. Am J Kidney Dis. 64(5): 793-803.
  5. Murray P.T., Mehta R.L., Shaw A., et al., (2014): Current use of biomarkers in acute kidney injury: report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int, 85(3):513-521.
  6. Naresh Y., Srinivas N., Vinapamula K.S., et al., (2018): Carbamylated hemoglobin can differentiate acute kidney injury from chronic kidney disease. Indian J Nephrol 28:187-90.
  7. Okaka E.I., Oforofuo I.A., Momoh S.M. (2012). A colorimetric method for measurement of carbamylated haemoglobin in patients with chronic kidney disease using a spectrophotometer. J Med Med Sci 3:494 8
  8. Pommerich D., Sonja K., Carola W., et al., (2015). Impact of carbamylation on three different methods, HPLC, capillary electrophoresis and TINIA of measuring HbA1c levels in patients with kidney disease. Diabetes Research and Clinical Practice. 108. 10.1016/j.diabres.2015.01.034.
  9. Stim J., Shaykh M., Anwar F., et al., (1995). Factors determining hemoglobin carbamylation in renal failure. Kidney Int 48:1605 10.
  10. Tahora S., Islam M.M., Jahan F., et al., (2021): Carbamylated Haemoglobin is an Early Biomarker to Predict Chronic Kidney Disease. Archives of Nephrology and Urology 4: 101-114.